Funder: National Institutes of Health
Due Dates (Anticipated): September 2026 (Full application deadline, projected)
Funding Amounts: Not specified; award ceiling/floor and total program funding not yet announced.
Summary: Supports preclinical pharmacodynamic, pharmacokinetic, and efficacy studies of therapeutic agents (small molecules or biologics) to advance treatments for neurological and related disorders.
Key Information: This is a forecasted opportunity; applications are not being solicited yet.